Alexandre Chan1, Deren Soh, Yu Ko, Yu-Chu Huang, Joen Chiang. 1. Department of Pharmacy, Faculty of Science, National University of Singapore, Block S4, 18 Science Drive 4, 117543, Singapore, Singapore, phaac@nus.edu.sg.
Abstract
BACKGROUND: Studies have examined drug-related problems (DRPs) that have led to hospital admissions in the general population. However, there is a lack of information on the characteristics of DRPs in the cancer population. OBJECTIVE: The objective of this study was to investigate the type, causality, severity, and preventability of DRPs that result in unplanned hospitalizations among cancer patients. METHODS: This was a prospective, cohort study conducted in two oncology wards between July and December 2012. All patients who were diagnosed with solid tumor or lymphoma and required unplanned hospitalization were included. The incidence of DRPs among hospital admissions was captured, and the nature of the DRPs (causality, severity, and preventability) was characterized. RESULTS: There were 1,299 admissions and 1,275 were eligible for analysis. Among the 1,275 eligible admissions, 158 (12.4%) were considered to be associated with a DRP. In the 158 admissions associated with DRPs, 164 DRPs were found. The majority of the DRP-related admissions were adverse drug reactions (ADRs) (n=155/164, 94.5%), probable (n=98, 59.8%), moderately severe (n=155, 94.5%), and probably or definitely preventable (n=86, 52.4%). Most patients with DRPs recovered and were discharged. Febrile neutropenia was the most common adverse drug reaction, and drug combinations involving antihypertensives and long-term corticosteroids raised the risks for potential drug-drug interactions among patients with cancer. CONCLUSION: The incidence of DRP-induced unplanned hospital admissions was 12.4% among cancer patients. Approximately half of these were preventable events.
BACKGROUND: Studies have examined drug-related problems (DRPs) that have led to hospital admissions in the general population. However, there is a lack of information on the characteristics of DRPs in the cancer population. OBJECTIVE: The objective of this study was to investigate the type, causality, severity, and preventability of DRPs that result in unplanned hospitalizations among cancerpatients. METHODS: This was a prospective, cohort study conducted in two oncology wards between July and December 2012. All patients who were diagnosed with solid tumor or lymphoma and required unplanned hospitalization were included. The incidence of DRPs among hospital admissions was captured, and the nature of the DRPs (causality, severity, and preventability) was characterized. RESULTS: There were 1,299 admissions and 1,275 were eligible for analysis. Among the 1,275 eligible admissions, 158 (12.4%) were considered to be associated with a DRP. In the 158 admissions associated with DRPs, 164 DRPs were found. The majority of the DRP-related admissions were adverse drug reactions (ADRs) (n=155/164, 94.5%), probable (n=98, 59.8%), moderately severe (n=155, 94.5%), and probably or definitely preventable (n=86, 52.4%). Most patients with DRPs recovered and were discharged. Febrile neutropenia was the most common adverse drug reaction, and drug combinations involving antihypertensives and long-term corticosteroids raised the risks for potential drug-drug interactions among patients with cancer. CONCLUSION: The incidence of DRP-induced unplanned hospital admissions was 12.4% among cancerpatients. Approximately half of these were preventable events.
Authors: Cornelis S van der Hooft; Miriam C J M Sturkenboom; Kees van Grootheest; Herre J Kingma; Bruno H Ch Stricker Journal: Drug Saf Date: 2006 Impact factor: 5.606
Authors: Rachel P Riechelmann; Ian F Tannock; Lisa Wang; Everardo D Saad; Nathan A Taback; Monika K Krzyzanowska Journal: J Natl Cancer Inst Date: 2007-04-18 Impact factor: 13.506
Authors: Cornelis S van der Hooft; Jeanne P Dieleman; Claire Siemes; Albert-Jan L H J Aarnoudse; Katia M C Verhamme; Bruno H C H Stricker; Miriam C J M Sturkenboom Journal: Pharmacoepidemiol Drug Saf Date: 2008-04 Impact factor: 2.890
Authors: A Antonuzzo; E Vasile; A Sbrana; M Lucchesi; L Galli; I M Brunetti; G Musettini; A Farnesi; E Biasco; N Virgili; A Falcone; S Ricci Journal: Support Care Cancer Date: 2016-09-11 Impact factor: 3.603
Authors: Dania M van der Meer; Tracey J Weiland; Jennifer Philip; George A Jelinek; Mark Boughey; Jonathan Knott; Claudia H Marck; Jennifer L Weil; Heather P Lane; Anthony J Dowling; Anne-Maree Kelly Journal: Support Care Cancer Date: 2015-08-26 Impact factor: 3.603
Authors: Sze Ling Chan; Xiaohui Ang; Levana L Sani; Hong Yen Ng; Michael D Winther; Jian Jun Liu; Liam R Brunham; Alexandre Chan Journal: Br J Clin Pharmacol Date: 2016-09-19 Impact factor: 4.335
Authors: Jane de Lemos; Peter Loewen; Cheryl Nagle; Robert McKenzie; Yong Dong You; Anna Dabu; Peter Zed; Peter Ling; Richard Chan Journal: BMJ Open Qual Date: 2021-01